ArticleBMC neurology2026
Facial diplegia as the first manifestation of Burkitt lymphoma with a Guillain-Barré syndrome-like presentation: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuillain-Barré syndrome (GBS) is among the most common causes of acute inflammatory polyneuropathy and may present with cranial nerve involvement, including facial diplegia. Rarely, hematologic malignancies can produce a GBS-compatible or GBS-like neurological phenotype, creating a diagnostic challenge in the acute setting. CASE PRESENTATION: A 50-year-old immunocompetent woman presented with bilateral facial paralysis, dysarthria, dysphagia, areflexia, and mild left upper-limb weakness. Cerebrospinal fluid (CSF) analysis showed albuminocytologic dissociation. Baseline electromyography and nerve conduction studies (EMG/NCS), performed early in the course, showed non-specific sensorimotor polyneuropathy without definitive demyelinating features. Because the clinical syndrome and CSF findings were compatible with a time-sensitive working diagnosis of GBS, intravenous immunoglobulin was initiated. Follow-up EMG/NCS in the second week evolved to show demyelinating features with secondary axonal involvement, compatible with GBS. However, rapidly progressive leukocytosis, markedly elevated lactate dehydrogenase and ferritin levels, profound weight loss, splenomegaly, para-aortic lymphadenopathy, and blast-like cells on peripheral smear prompted parallel hematologic reassessment. Peripheral blood flow cytometry was consistent with Burkitt lymphoma, and repeat CSF flow cytometry demonstrated a CD10 + germinal center-derived B-cell neoplastic population, indicating central nervous system involvement. The patient subsequently deteriorated with aspiration pneumonia, sepsis/shock, and a fatal course before lymphoma-directed chemotherapy could be initiated.
conclusionsBurkitt lymphoma with central nervous system involvement can present with a GBS-compatible acute neuropathic phenotype, including facial diplegia. The initial diagnosis of GBS may be clinically reasonable in a time-sensitive setting; however, major systemic and hematologic red flags should prompt early parallel evaluation for malignancy. Peripheral blood and CSF flow cytometry may provide decisive diagnostic evidence when biopsy or further work-up is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.